This site allows you to submit a proposal(s) for Medical Educational Grants, Sponsorship Requests, Charitable Contributions and/or Donations, and Patient Advocacy Charitable Contributions.

Note, all requests must be submitted at least thirty (30) business days prior to the date you require a decision or a minimum of 30-days prior to your program start date. Please contact if you have a proposal that requires an expedited review process.

When submitting a request, you will be guided through the electronic submission process through instructions and help options. Please make sure that you complete each required field designated by an asterisk (*). Should we need additional information, we will notify you via an email sent to the address you provided upon registration.

We will review all requests. Please note that submission of a request does not indicate that we have agreed to provide support. Support decisions are made only after BioCryst has reviewed your complete request. You will be notified of the decision via an email sent to the address you provided upon registration. All decisions are final.

This site is intended to be used for submitting requests for support of:

  • Medical Educational Requests: Support for independent accredited or unaccredited medical education activities or education directed to healthcare professionals, healthcare organizations, patient organizations, patients, or other members of the healthcare community.

  • Patient Advocacy - Charitable Contributions: Financial or in-kind contributions to patient advocacy groups and organizations with not-for-profit status, where the primary purpose of the contribution is charitable or philanthropic. Unlike for Sponsorship requests, BioCryst does not expect to receive any benefit, consideration, or service in return for Charitable Contributions to patient advocacy organizations.

  • Sponsorships Requests: Funding to an eligible entity including patient advocacy organizations for events or activities in exchange for tangible benefits from the funding recipient, such as the opportunity for BioCryst advertisements at an event or activity, exhibit space at an event, admission to certain events, etc.

  • Charitable Contributions: Financial or in-kind contributions to non-patient advocacy organizations and projects that fall into BioCryst’s Corporate Social Responsibility categories of STEM education, diversity, equity & inclusion, and food insecurity. Organizations should be recognized as charitable under local law, where the primary purpose of the contribution is charitable or philanthropic.

Our Areas of Interest include:

  • Medical - HAE:
    • Defining overall disease burden for patients, families and others impacted by HAE/bradykinergic angioedema
      • Understanding HAE disease and treatment burden on quality of life (including physical and mental health impacts) on patients and caregivers
      • Healthcare utilization costs and financial burden of HAE
      • Evolution of understanding and classification of bradykinergic angioedema syndromes (i.e.,C1-nl-HAE, hereditary, acquired, contact pathway mutations)
    • Redefining HAE/bradykinergic angioedema Disease Management Goals and Optimal Outcomes
      • Diagnosis, management and outcome measures of success for patients living with HAE/bradykinergic angioedema (including optimal mental health outcomes)
      • Review of Treatment Guidelines/Recommendations
      • Individualizing support and shared decision making to improve patient experience and long-term goals for success
        • Options on switching from previous prophylaxis, on-demand treatment, and patient-specific considerations for approved therapies (individualized approach)
      • Diagnosis and management of pediatric patients with HAE/bradykinergic angioedema

  • Medical - Pipeline:
    • Treatment Goals for Complement-Mediated Diseases (priority on Rare Renal Diseases)
    • Emerging Therapies for Complement-Mediated Diseases with emphasis on Factor D inhibition
    • Unmet Medical Needs with current Standards of Care (SoC) for Rare Renal Diseases
    • Clinical Treatment paradigms for PNH and Rare Renal diseases
    • Treatment modalities in complement-mediated disease
    • Role of Proximal vs. Terminal complement targeting in renal disease
    • Complement Biology for the Clinician with emphasis on Nephrology
    • Methods to improve feasibility of patient enrollment for clinical trials in rare diseases
    • Clinical/clinical research strategies to improve patient outcomes in PNH and Complement-mediated Renal disease

  • Patient Advocacy: 
    • Local, regional and global patient advocacy focused on:
      • HAE
      • Rare hematological conditions 
      • Kidney conditions
      • Broader rare disease community